FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International (OTCBB: OXIS; Nouveau Marche: OXIS) (FWB: OXI), a biopharmaceutical company focused on commercializing predictive biomarkers, clinical assays and nutraceutical and therapeutic products, announced today that it has identified a new predictive diagnostic lipoprotein biomarker that has the ability to detect early cardiovascular disease.
